Compare Tempus AI (TEM) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Xylem, Inc. — how do they compare? Tempus AI trades at $70.09 (market cap $12.58B), while Xylem, Inc. trades at $101.09 (market cap $23.81B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.69% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 22 Days and Xylem, Inc. for 50 Days on average.
| TEM | XYL | |
|---|---|---|
Market Cap | $12.58B | $23.81B |
Volume | 7,444,569 | 2,234,713 |
Sector | Broad Market / Factor | Industrials |
52-Week High | $99.28 | $152.95 |
52-Week Low | $41.55 | $100.92 |
Typical Hold Time | 22 Days | 50 Days |
Enterprise Value | $13.21B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $72.15, up 2.65% today, with a bullish technical signal and strong analyst support. The stock shows recent earnings beats but remains unprofitable, with a net income margin of -17.77% for 2026. Positive developments include FDA clearance for an AI product and expanded data partnerships, fueling investor optimism in the healthtech sector.
Outlook is cautiously optimistic given growth potential in AI-driven diagnostics, but high valuation (P/S 8.61) and persistent losses pose risks. Upside hinges on revenue scaling and path to profitability, with a consensus price target of $72.60 suggesting limited near-term gains from current levels.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent revenue growth from $5.5B in 2022 to $9.0B in 2025 and net income margin expanding to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen its industrial water solutions portfolio. XYL has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected on October 27, 2026.
Analyst consensus is mixed with 47.5% buy ratings and a $149.13 price target suggesting 46% upside. Key risks include China market weakness and increased debt from recent acquisitions. The stock offers value with reasonable P/E of 24.28 and strong cash flow generation, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
